Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Exicure grosses $22mm via PIPE

Executive Summary

Exicure Inc. (gene regulatory and immunotherapeutic drugs) grossed $22mm through the private placement of 4.9mm shares (a 10% discount) at $4.50 each to investors including Sphera Global Healthcare, Knoll Capital Management, Broadfin Capital, and Sio Capital Management. Exicure will use the funds for ongoing development of its pipeline candidates, including Phase I AST008 for solid tumors and Phase I XCUR17 for psoriasis. Ladenburg Thalmann, Castle Hill Capital Partners, and Katalyst Securities were the placement agents.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies